A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension

Nadine D Arnold, Josephine A Pickworth, Laura E West, Sarah Dawson, Joana A Carvalho, Helen Casbolt, Adam T Braithwaite, James Iremonger, Lewis Renshall, Volker Germaschewski, Matthew McCourt, Philip Bland-Ward, Hager Kowash, Abdul G Hameed, Alexander M K Rothman, Maria G Frid, A A Roger Thompson, Holly R Evans, Mark Southwood, Nicholas W MorrellDavid C Crossman, Moira K B Whyte, Kurt R Stenmark, Christopher M Newman, David G Kiely, Sheila E Francis, Allan Lawrie

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Current treatments increase life expectancy but have limited impact on the progressive pulmonary vascular remodelling that drives PAH. Osteoprotegerin (OPG) is increased within serum and lesions of patients with idiopathic PAH and is a mitogen and migratory stimulus for pulmonary artery smooth muscle cells (PASMCs). Here, we report that the pro-proliferative and migratory phenotype in PASMCs stimulated with OPG is mediated via the Fas receptor and that treatment with a human antibody targeting OPG can attenuate pulmonary vascular remodelling associated with PAH in multiple rodent models of early and late treatment. We also demonstrate that the therapeutic efficacy of the anti-OPG antibody approach in the presence of standard of care vasodilator therapy is mediated by a reduction in pulmonary vascular remodelling. Targeting OPG with a therapeutic antibody is a potential treatment strategy in PAH.

Original languageEnglish
Article number5183
JournalNature Communications
Early online date15 Nov 2019
Publication statusPublished - 1 Dec 2019


Dive into the research topics of 'A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this